Immunize Org

01/10/2026

This child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options.

You’ll find this answer, as well as other COVID-19 vaccine Q&As, here: www.immunize.org/ask-experts/topic/covid-19.

01/09/2026

The ImmunizeOrg website offers a wealth of resources to support your vaccination practice. You’ll find “What If You Don’t Vaccinate Your Child?” here: https://www.immunize.org/wp-content/uploads/catg.d/p4017.pdf.

This 1-page PDF (last updated November 2025) is free to download, print, and share.

01/08/2026

Take a stand without saying a word with our new, elegant “Vaccination Saves Lives” lapel pins. Wear them yourself or gift them to others to display on clothing, white coats, backpacks, or tote bags.

The pin comes in two backing options—two slide posts, held securely by either rubber or locking-metal backings, and new magnetic clasps that hold the pin firmly without piercing fabric.

View more details at: https://shop.immunize.org/collections/vaccines-save-lives-pins.

01/08/2026

Anxiety about needles is common in children and adults. For some, anxiety can lead them to delay or avoid vaccination, even if they know it’s important. ImmunizeOrg’s president and CEO, Dr. Kelly L. Moore offers practical advice for healthcare professionals and the public in the Improving the Vaccination Experience Video Series. Each video is about 4 minutes long.

Find today’s video here: www.youtube.com/watch?v=SIfmCrfI85w

This video explains in simple terms why some people feel dizzy or faint around the time of vaccination. It provides practical ways to address anxiety and red...

01/07/2026

Get the immunization news you need in this week’s issue of IZ Express.

More Top Stories include:
* CDC adopts individual decision-making for HepB vaccination of infants born to women who test negative for the virus
* Measles: 2025 ends with 2,065 confirmed cases and ongoing outbreaks in three states

Read the entire issue online:
www.immunize.org/news/iz-express/issue/1851

50,000+ healthcare professionals rely on IZ Express to keep up to date on new and updated vaccine recommendations from CDC, notable publications, and vaccination resources from ImmunizeOrg and our partners.

Subscribe for free today: www.immunize.org/news/iz-express/about/

01/06/2026

Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older

mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older

Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older

Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older

Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired.

You’ll find this answer, as well as other COVID-19 vaccine Q&As, here: www.immunize.org/ask-experts/topic/covid-19.

01/06/2026

Register for an Immunize​.org Website Office Hours Zoom session to learn simple tips and tricks for using our website efficiently. Each 30-minute session opens with a tour of our Vaccines A–Z website section. You will be able to ask your questions live or submit them when you register for the session.

Register now for the next Immunize​.org Website Office Hours Zoom session.

Registration for Wednesday, January 7 at 4:00 p.m. ET: https://tinyurl.com/3kxd3atx

Registration for Thursday, January 8 at 12:00 p.m. ET: https://tinyurl.com/ysxxepc4

01/05/2026

The ImmunizeOrg website offers a wealth of resources to support your vaccination practice. You’ll find “Vaccinations for Adults with Lung Disease” here: www.immunize.org/wp-content/uploads/catg.d/p4045.pdf.

This 1-page PDF document (last updated October 2025) is free to download, print, and share.

01/05/2026

Today’s Ask the Experts question and answer is presented by ImmunizeOrg’s president and CEO, Dr. Kelly L. Moore. Established more than 25 years ago, our popular Ask the Experts feature offers answers to more than a thousand questions about vaccines and their administration. We regularly add new questions and answers to this feature, and review and revise all information to reflect current ACIP recommendations.

Find today’s video here: www.youtube.com/watch?v=1mBzeet9KY4

Welcome to Immunize.org’s Ask the Experts resources. This Ask the Experts question is presented by Immunize.org’s Kelly L. Moore, MD, MPH. Question: What is ...

01/04/2026

We love hearing from the healthcare and public health professionals we serve about how they use the news and resources we provide. Everyone who recommends or administers vaccines is welcome to visit our website and subscribe to our free weekly newsletter, IZ Express.

We are here to provide the trusted, timely information you need to support the delivery of safe and effective immunization services for people of all ages.

Visit us at www.immunize.org.

Join 50,000+ subscribers to our free weekly IZ Express newsletter at: www.immunize.org/news/iz-express/about/ .

01/03/2026

Because COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low.

A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness.

You’ll find this answer, as well as other COVID-19 vaccine Q&As, here: www.immunize.org/ask-experts/topic/covid-19.

01/02/2026

The ImmunizeOrg website offers a wealth of resources to support your vaccination practice. You’ll find “QR Code Links to Vaccine Information Statement (VIS) Translations: Influenza (Flu) Vaccine (Inactivated or Recombinant)” here: www.immunize.org/wp-content/uploads/catg.d/p2092.pdf.

This 3-page PDF (last updated October 2025) is free to download, print, and share.